Orphazyme AS (CHIX:ORPHAC) Capital Expenditure : kr-0.19 Mil (TTM As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Orphazyme AS's cash flow for capital expenditures for the three months ended in Jun. 2022 was kr0.00 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Jun. 2022 was kr-0.19 Mil.

Orphazyme AS Capital Expenditure Historical Data

The historical data trend for Orphazyme AS's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS Capital Expenditure Chart

Orphazyme AS Annual Data

Trend

Jun14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Capital Expenditure

Get a 7-Day Free Trial

-1.49

-2.35

-3.29

-5.10

-0.99

Orphazyme AS Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Capital Expenditure	Get a 7-Day Free Trial									-1.76	-3.34	-0.81	-0.19	-

Orphazyme AS Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.19 Mil.

Orphazyme AS (CHIX:ORPHAC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Capital Expenditure

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200

Website

https://www.orphazyme.com

Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS (CHIX:ORPHAC) Headlines

No Headlines